The main aim of this thesis was to assess the efficacy and safety of pasireotide LAR treatment in patients with acromegaly controlled with first-generation somatostatin analogues and pegvisomant.
In chapters 3 and 4 we report the results of the PAsireotide LAR and PEgvisomant study (PAPE) study.
Chapter 5 we assessed whether somatostatin receptor subtype 2 and 5 protein expression correlates and predicts response to pasireotide LAR treatment in the PAPE study.
In chapter 6 we assessed plasma acylated and unacylated ghrelin levels in acromegaly patients using first-generation somatostatin analogues and pegvisomant combination treatment.
Finally in chapter 7 we report the results of a pilot study evaluating whether pegvisomant is expressed in the liver and wheter kupffer cells are involved in the clearance of pegvisomant in two patients with acromegaly.

Additional Metadata
Keywords acromegaly, pituitary, pasireotide, somatostatin, pegvisomant, growth hormone, clinical trial
Promotor A.J. van der Lelij (Aart Jan) , S.J.C.M.M. Neggers (Bas)
Publisher Erasmus University Rotterdam
ISBN 978-94-6361-304-0
Persistent URL hdl.handle.net/1765/118967
Note For copyright reasons there is a partial embargo for this dissertation
Citation
Muhammad, A. (2019, September 10). Novel Insights in the Modern Medical Management of Acromegaly. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/118967